The size of the Europe Contrast Media Market was worth USD 1.41 Billion in 2020. This value is estimated to grow at a CAGR of 5.2% to reach USD 1.82 billion by 2025. The Europe Contrast Media market is growing at a slow rate.
Growing awareness regarding the interventional diagnosis and chronic disease treatment options is estimated to support the European contrast media market. A growing number of European government initiatives to increase the awareness regarding cancer and cardiac diagnosis and innovative products launched by many of the companies is further predicted to drive the market growth.
Favorable reimbursement scenarios for contrast media used for cardiovascular diagnosis and robust healthcare infrastructure in European regions. Increasing demand for image-guided diagnostics and procedures, growing regular and occurrence rates of cardiac diseases, and cancer are favorable factors.
Factors like side-effects associated with the usage of contrast media, high costs related, and lack of awareness are estimated to hamper the market growth to a limited extent in Europe.
This research report on the European Contract Media Market has been segmented and sub-segmented into the following categories:
By Medical Procedure:
By Route of Administration:
By Type:
By Indications:
By Application:
By Country:
Europe had a low CAGR during the forecast period. The reasons for the same might be government policies.
In Europe, the United Kingdom is leading the market with the highest share due to the presence of the vital diagnostic companies existing in the country. Increasing R&D activities of contrast agents and increased usage of interventional X-ray for different diagnosis applications favor the market in the United Kingdom.
The German market is predicted to grow at a healthy rate from 2020 to 2025 due to the growing demand for minimally invasive surgical processes and the increasing number of patients with cardiovascular diseases worldwide.
European countries like France and Italy are expected to have robust growth during the forecast period. Regular increase of neurological, cancer, and cardiovascular, rising partnerships, and acquisitions amidst the key players in launching new products and evolving innovations over the contrast media are factors expanding the market growth.
Companies like CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy) in 2015. Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), and Subhra Pharma Private Limited (India) are the leaders in the Europe Contrast Media market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Medical Procedure
5.1.1 Introduction
5.1.2 X-Ray/CT
5.1.3 MRI
5.1.4 Ultrasound
5.1.5 Y-o-Y Growth Analysis, By Medical Procedure
5.1.6 Market Attractiveness Analysis, By Medical Procedure
5.1.7 Market Share Analysis, By Medical Procedure
5.2 Route of Administration
5.2.1 Introduction
5.2.2 Injectable Contrasts Media
5.2.3 Oral Contrasts Media
5.2.4 Rectal Contrasts Media
5.2.5 Urethral Contrasts Media
5.2.6 Y-o-Y Growth Analysis, By Route of Administration
5.2.7 Market Attractiveness Analysis, By Route of Administration
5.2.8 Market Share Analysis, By Route of Administration
5.3 Type
5.3.1 Introduction
5.3.2 Iodinated Contrasts Media
5.3.3 Gadolinium-Based Contrasts Media
5.3.4 Microbubble Contrasts Media
5.3.5 Barium- Based Contrasts Media
5.3.6 Y-o-Y Growth Analysis, By Type
5.3.7 Market Attractiveness Analysis, By Type
5.3.8 Market Share Analysis, By Type
5.4 Indications
5.4.1 Introduction
5.4.2 Cardiovascular Disorders
5.4.3 Oncology
5.4.4 Neurological Disorders
5.4.5 Gastrointestinal Disorders
5.4.6 Nephrological Disorders
5.4.7 Musculoskeletal Disorders
5.4.8 Y-o-Y Growth Analysis, By Indications
5.4.9 Market Attractiveness Analysis, By Indications
5.4.10 Market Share Analysis, By Indications
5.5 Application
5.5.1 Introduction
5.5.2 Radiology
5.5.3 Interventional Cardiology
5.5.4 Interventional Radiology
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Medical Procedure
6.1.3.3 By Route of Administration
6.1.3.4 By Type
6.1.3.5 By Indication
6.1.3.6 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Medical Procedure
6.1.4.3 By Route of Administration
6.1.4.4 By Type
6.1.4.5 By Indication
6.1.4.6 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Medical Procedure
6.1.5.3 By Route of Administration
6.1.5.4 By Type
6.1.5.5 By Indication
6.1.5.6 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Medical Procedure Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Spago Nanomedical AB
8.3 Subhra Pharma Private Limited
8.4 Daiichi Sankyo
8.5 CMC Contrast AB
8.6 Nanopet Pharma GmbH
8.7 Guerbet Group
8.8 Bracco Imaging S.P.A
8.9 Bayer AG
8.10 Lantheus Medical Imaging (Subsidiary of Lantheus Holdings, Inc.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
